| Just Other Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > PR > Top Five Publicity Myths |
|
Just Other Articles - Top Five Publicity Myths
Most people consider getting publicity the most important part of public relations. It's also very According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product mysterious to many people. Here are my top five publicity myths, to help make publicity better unde ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in rstood. 1. Who you (or your publicist) knows at the media is more important than the story idea. S lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ure, it's easier to get a reporter or writer that knows you to listen to your pitch. But unless the here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe pitch is good, it doesn't matter if your contacts are your best friends -- they won't risk their jo d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro bs on your bad idea. 2. The amount of time spent on an interview determines how much publicity you ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc will receive. I know people who have been interviewed for an hour and a half, and have only receive easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi d a line in a publication (or none at all). I also know people who were interviewed for 20 minutes nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically who received a half-page profile. It all depends on the story the writer is putting together, who e and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ lse they are interviewing, and editorial decisions. 3. You have control over the information presen ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ted. One of the differences between advertising and publicity is that you pay for advertising and p ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ublicity is "free." Another difference is that by paying for advertising, you control the message. dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod The publicity you receive may contain an inaccurate quote, or may present your information in a dif cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ferent way than you had intended. These are possibilities, and should be taken in stride. 4. A pub tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen licist can guarantee media coverage. Unless it is paid for, there is no guarantee of coverage. Eve t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel n something that has a target broadcast or publication date can be moved if a hot story overshadows ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust yours. 5. The media will jump on a great idea and work on the story immediately. What may seem lik y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products e the greatest news in the world to you (and might actually be) is just one of many "hot" pitches th . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de at the media receive. Unless it is a major event (usually a grim one), the media takes their time d elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip etermining their interest in a story. That's why constant follow-up is so necessary for all pitches tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Hurdles to Cross Cultural Business Communication Should You Take One of Their Free Customer Reward Cards? Increasing Productivity and Efficiency in Modern Corporations
|